F‑box proteins involved in cancer‑associated drug resistance (Review)

  • Authors:
    • Jian Gong
    • Yuqian Zhou
    • Deliang Liu
    • Jirong Huo
  • View Affiliations

  • Published online on: April 16, 2018     https://doi.org/10.3892/ol.2018.8500
  • Pages: 8891-8900
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The ubiquitin proteasome system (UPS) regulated human biological processes through the appropriate and efficient proteolysis of cellular proteins. F‑box proteins are the vital components of SKP1‑CUL1‑FBP (SCF)‑type E3 ubiquitin ligases that determine substrate specificity. As F‑box proteins have the ability to control the degradation of several crucial protein targets associated with drug resistance, the dysregulation of these proteins may lead to induction of chemoresistance in cancer cells. Chemotherapy is one of the most conventional therapeutic approaches of treatment of patients with cancer. However, its exclusive application in clinical settings is restricted due to the development of chemoresistance, which typically results treatment failure. Therefore, overcoming drug resistance is considered as one of the most critical issues that researchers and clinician associated with oncology face. The present review serves to provide a comprehensive overview of F‑box proteins and their possible targets as well as their correlation with the chemoresistance and chemosensitization of cancer cells. The article also presents an integrated representation of the complex regulatory mechanisms responsible for chemoresistance, which may lay the foundation to explore sensible candidate drugs for therapeutic intervention.
View Figures
View References

Related Articles

Journal Cover

June-2018
Volume 15 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Gong J, Zhou Y, Liu D and Huo J: F‑box proteins involved in cancer‑associated drug resistance (Review). Oncol Lett 15: 8891-8900, 2018
APA
Gong, J., Zhou, Y., Liu, D., & Huo, J. (2018). F‑box proteins involved in cancer‑associated drug resistance (Review). Oncology Letters, 15, 8891-8900. https://doi.org/10.3892/ol.2018.8500
MLA
Gong, J., Zhou, Y., Liu, D., Huo, J."F‑box proteins involved in cancer‑associated drug resistance (Review)". Oncology Letters 15.6 (2018): 8891-8900.
Chicago
Gong, J., Zhou, Y., Liu, D., Huo, J."F‑box proteins involved in cancer‑associated drug resistance (Review)". Oncology Letters 15, no. 6 (2018): 8891-8900. https://doi.org/10.3892/ol.2018.8500